First Time Loading...

Chromadex Corp
NASDAQ:CDXC

Watchlist Manager
Chromadex Corp Logo
Chromadex Corp
NASDAQ:CDXC
Watchlist
Price: 3.65 USD -0.54%
Updated: Mar 28, 2024

Intrinsic Value

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. [ Read More ]

The intrinsic value of one CDXC stock under the Base Case scenario is 1.74 USD. Compared to the current market price of 3.65 USD, Chromadex Corp is Overvalued by 52%.

Key Points:
CDXC Intrinsic Value
Base Case
1.74 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Chromadex Corp

Backtest CDXC Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CDXC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Chromadex Corp

Current Assets 49.5m
Cash & Short-Term Investments 27.2m
Receivables 5.2m
Other Current Assets 17.1m
Non-Current Assets 5.4m
PP&E 4.5m
Intangibles 510k
Other Non-Current Assets 383k
Current Liabilities 20.6m
Accounts Payable 10.2m
Accrued Liabilities 10.2m
Other Current Liabilities 206k
Non-Current Liabilities 5.9m
Long-Term Debt 12k
Other Non-Current Liabilities 5.9m
Efficiency

Earnings Waterfall
Chromadex Corp

Revenue
83.6m USD
Cost of Revenue
-32.8m USD
Gross Profit
50.8m USD
Operating Expenses
-56.4m USD
Operating Income
-5.6m USD
Other Expenses
661k USD
Net Income
-4.9m USD

Free Cash Flow Analysis
Chromadex Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CDXC Profitability Score
Profitability Due Diligence

Chromadex Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Chromadex Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

CDXC Solvency Score
Solvency Due Diligence

Chromadex Corp's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
48/100
Solvency
Score

Chromadex Corp's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CDXC Price Targets Summary
Chromadex Corp

Wall Street analysts forecast CDXC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CDXC is 5.09 USD with a low forecast of 2.32 USD and a high forecast of 7.35 USD.

Lowest
Price Target
2.32 USD
36% Downside
Average
Price Target
5.09 USD
39% Upside
Highest
Price Target
7.35 USD
101% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CDXC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CDXC Price
Chromadex Corp

1M 1M
+112%
6M 6M
+159%
1Y 1Y
+135%
3Y 3Y
-57%
5Y 5Y
-11%
10Y 10Y
-34%
Annual Price Range
3.65
52w Low
1.28
52w High
3.84
Price Metrics
Average Annual Return -14.69%
Standard Deviation of Annual Returns 30.63%
Max Drawdown -94%
Shares Statistics
Market Capitalization 273.7m USD
Shares Outstanding 75 309 104
Percentage of Shares Shorted 2.19%

CDXC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Chromadex Corp Logo
Chromadex Corp

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

273.7m USD

Dividend Yield

0%

Description

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 115 full-time employees. The company went IPO on 2007-06-25. NAD+ is a coenzyme and a regulator of cellular metabolism. The company operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Contact

CALIFORNIA
Los Angeles
10900 Wilshire Blvd Ste 600
+13103886706.0
https://chromadex.com/default.aspx

IPO

2007-06-25

Employees

115

Officers

Co-Founder & Chairman
Mr. Frank Louis Jaksch Jr.
CEO & Director
Mr. Robert N. Fried
Chief Financial Officer
Ms. Brianna Gerber
Senior Vice President of Global Regulatory & Scientific Affairs
Dr. Andrew Shao Ph.D.
Senior VP of Legal & Corporate Secretary
Heather Van Blarcom
Vice President of Global Marketing & Communications
Alex Worsham
Show More
Senior Vice President of People Matters
Mr. David Kroes
Managing Director of Asia Pacific
Ms. Chu Yan
Senior Vice President of Business Development
Mr. Jason Campbell
Head of Media Relations & Partnerships
Kendall Knysch
Show Less

See Also

Discover More
What is the Intrinsic Value of one CDXC stock?

The intrinsic value of one CDXC stock under the Base Case scenario is 1.74 USD.

Is CDXC stock undervalued or overvalued?

Compared to the current market price of 3.65 USD, Chromadex Corp is Overvalued by 52%.